The chief executive’s choice of words on Friday was telling. “The obesity market is not a zero-sum game,” Mike Doustdar told Reuters, reaching for an analogy from the company’s own history — a dozen insulin brands once coexisted, so why not the same for GLP-1 therapies? It is the kind of reassurance a company typically offers when the share price tells a different story. Novo Nordisk’s stock has shed roughly ten percent over the past year, trading at 39.37 euros on Friday, down 2.7 percent from the prior close.
The defensive tone is understandable. The Danish pharmaceutical giant finds itself squeezed from multiple directions simultaneously: intensifying competition from Eli Lilly, mounting pricing pressure in the US, a fresh cybersecurity incident, and an analyst community that is increasingly cooling on the investment case.
Berenberg Pulls the Buy Rating
The latest blow came from Berenberg, which downgraded Novo Nordisk from “Buy” to “Hold” on Thursday. Analyst Kerry Holford trimmed the price target for the Copenhagen listing to 305 Danish kroner from 325 kroner, arguing that the investment thesis had fully played out. Expectations for the Wegovy pill, she noted, were already priced into the stock during the first half of 2026 — while competitive pressure from Eli Lilly continues to build.
The timing was awkward. On the same day Berenberg published its downgrade, Lilly’s oral diabetes drug Foundayo received approval from UK regulators. Berenberg’s analysts pointed to the expected FDA approval of Lilly’s oral diabetes treatment as a particular concern. BMO Capital also issued a “Hold” rating on the stock the same day.
The downgrade lands during an already turbulent stretch. Novo Nordisk’s half-year results roughly two weeks ago initially drew a 2.9 percent gain, but sentiment has soured since. Disappointing trial data about a week ago cost the stock another percentage point, and even an expanded share buyback program announced around the same time failed to stem a 12.6 percent decline over that period. The shares now sit roughly 28 percent below their 52-week high.
The Competitive Arithmetic
Doustdar’s numbers do tell a story of market leadership. The oral Wegovy pill has reached over five million patients since its January 5 launch, with 265,000 weekly prescriptions in the week ending July 17. Second-quarter revenue from the pill reached approximately $500 million, obesity sales grew 16 percent, and total company revenue hit 23.15 billion Danish kroner — roughly $3.6 billion.
By comparison, Lilly’s Foundayo generated just $98 million in the same quarter, a figure that Leerink analyst David Risinger himself called “disappointing.” On paper, the gap looks comfortable.
But the competitive narrative has shifted beyond simple sales comparisons. Lilly is applying pressure through multiple channels — scientific, commercial, and legal. Late July saw Novo Nordisk file a lawsuit against Lilly in federal court in New Jersey, accusing the rival of misleading advertising. The complaint alleges Lilly’s comparison campaigns pit a lower Wegovy dosage against the highest dose of Zepbound. Novo Nordisk is seeking a permanent injunction and corrective advertising.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
There was some legal relief on another front: a Dutch court granted an injunction about a week ago against an unlawfully manufactured nasal spray containing compounded semaglutide, a win for the company’s patent protection. But the patent picture remains tense. Sandoz filed a challenge in late June at the Unified Patent Court in Milan against a Novo Nordisk patent covering the 1-milligram semaglutide dosage, which applies across 18 EU countries.
Pricing, Politics, and the New Reality
Perhaps the most telling shift is where Novo Nordisk is now spending its energy. Rather than purely growth narratives, the company is increasingly focused on pricing and access questions.
Novo Nordisk has announced it will cut list prices for Ozempic, Rybelsus, and Wegovy to $675 per month starting January 1, 2027 — down from over $1,000. The change applies only to patients in list-price-linked plans, not self-payers. President Jamey Millar cited demands from the US Congress as the driver. The backdrop is uncomfortable: the CagriSema study missed its goal, Lilly’s Zepbound keeps growing, and a Navitus survey shows 70 percent of GLP-1 users cite cost as the decisive factor in their medication choice.
In Australia, the company is lobbying for a phased inclusion of Ozempic and Wegovy in the government’s PBS subsidy program. Oceania chief Michael Azrak argues obesity costs the Australian economy $40 billion annually and that access to medication should not depend on patients’ ability to pay. The message is clear: the bottleneck for Novo Nordisk is no longer primarily in research, but in reimbursement policy across health systems.
The Data Breach Shadow
Adding to the strain, the hacker group FulcrumSec on Friday released what appears to be stolen Novo Nordisk data following a failed extortion attempt — 30 models, 70 datasets, and roughly 0.5 terabytes of microscope images from a laboratory platform. The company has not publicly commented, and Doustdar remained silent on the matter.
Meanwhile, a lawsuit against Hims & Hers over allegedly patent-infringing weight-loss knockoffs continues, and the FDA has raised concerns about Novo Nordisk’s own Wegovy advertising.
A Market Not Fully Convinced
Institutional investors show a split picture. Mirae Asset Global Investments significantly increased its position in the second quarter, as did QV Investors and Signaturefd. The broader analyst consensus leans “Hold.”
The stock trades about 28 percent below its 52-week high of 54.86 euros and nearly 4.8 percent below its 50-day average. For all of Doustdar’s confidence that the obesity market can accommodate multiple winners, the market’s pricing suggests investors are not yet ready to fully embrace that view — at least not while the competitive, regulatory, and reputational pressures keep stacking up.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 14 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 14.
Novo Nordisk: Buy or sell? Read more here...
